The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward
BACKGROUND: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy developed for bladder cancer. This non-replicating recombinant adenoviru...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2024-06-01
|
| Series: | Bladder Cancer |
| Acceso en liña: | https://doi.org/10.3233/BLC-230083 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|